SAN DIEGO, Oct. 27, 2015 /PRNewswire/ -- Beloteca, Inc., a specialty pharmaceutical company focused on the development of sterile pharmaceutical products with an emphasis on generics and 505(b)(2) reformulations, today announced that it has opened its product development laboratory in San Diego, California.
"This new laboratory helps Beloteca achieve its mission of developing multiple products per year," said Fred Defesche, Chief Executive Officer of Beloteca, Inc. "It also allows Beloteca to take greater control over project timelines and the development process."
"The new laboratory establishes Beloteca's in-house product development capabilities allowing the evaluation of development projects prior to initiating full development creating a more nimble and aggressive approach to project selection. Additionally, the new laboratory will be used for many of Beloteca's analytical and formulation development activities enabling Beloteca to develop many of its products in house," stated Dorla Mirejovsky, Chief Scientific Officer of Beloteca.
Beloteca is a privately held specialty pharmaceutical company. Beloteca's primary focus is to develop and obtain regulatory approval for sterile pharmaceutical products with an emphasis on generics and 505(b)(2) reformulations. We target niche and difficult to manufacture products. For additional information about the Company, visit the Company's web site at www.beloteca.com.
For further information, please contact Fred Defesche at 512-669-8765 or via email [email protected].
"This new laboratory helps Beloteca achieve its mission of developing multiple products per year," said Fred Defesche, Chief Executive Officer of Beloteca, Inc. "It also allows Beloteca to take greater control over project timelines and the development process."
"The new laboratory establishes Beloteca's in-house product development capabilities allowing the evaluation of development projects prior to initiating full development creating a more nimble and aggressive approach to project selection. Additionally, the new laboratory will be used for many of Beloteca's analytical and formulation development activities enabling Beloteca to develop many of its products in house," stated Dorla Mirejovsky, Chief Scientific Officer of Beloteca.
Beloteca is a privately held specialty pharmaceutical company. Beloteca's primary focus is to develop and obtain regulatory approval for sterile pharmaceutical products with an emphasis on generics and 505(b)(2) reformulations. We target niche and difficult to manufacture products. For additional information about the Company, visit the Company's web site at www.beloteca.com.
For further information, please contact Fred Defesche at 512-669-8765 or via email [email protected].
RSS Feed